Overview

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Nafamostat